Market Access Sponsored The pre-commercial case for connecting data before acquiring... For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.
Market Access UK’s next pricing and access scheme to last for 7 years Operational review meeting minutes released by the DHSC reveal industry and government are planning to move to a 7-year agreement.
Market Access One year after MFN: How US policy is reshaping the global ph... Just over a year has passed since the Trump administration sent letters to 17 leading manufacturers demanding steps towards MFN pricing.
Market Access Beyond Market Access: Why healthcare-system understanding is... Healthcare-system literacy, and the ability to contribute to system shaping, must become part of how healthcare leaders make decisions.
Market Access Is the next generation of Chinese biotech ready to go global... Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?
Market Access What the revised 340B rebate pilot programme means for pharm... While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.
Oncology ESMO26: Taiho Oncology on improving the lives of patients wi... Dr Harold Keer, chief medical officer at Taiho Oncology, discusses the Phase 2 REZILIENT2 trial data presented at ESMO26 and the NSCLC setting.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.